arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Skye Bioscience, Inc.

SKYE
$0.53 ▲ +0.04 (+8.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Skye Bioscience, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $21.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -290.5%
FCF / Share $-1.09
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-55.92M
↓ -110.5%
FCF / Share Free cash flow per share
$-1.09
↓ -47.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 60 quarters